Expiratory abdominal muscle thickness, a new point of care ultrasound measure for respiratory muscle mass in the intensive care unit: a prospective observational cohort study - 21/09/23
, Yoann Boudina a, Ophélie Dransart-Raye a, Justine Perrot a, Ayoub Ouahrani a, Pierre-Grégoire Guinot a, b, c, d, Bélaïd Bouhemad a, b, c, dHighlights |
• | Expiratory muscles are key respiratory muscles in critically ill patients |
• | Expiratory muscles thickness can be easily measured by ultrasonography |
• | Expiratory muscles thickness is associated with mortality |
• | Ultrasound measurement of expiratory muscles might provide a marker of respiratory muscle mass |
Abstract |
Background |
Even if expiratory muscles are key muscles in intensive care unit (ICU) patients, the association between their thickness and mortality has never been assessed. This study aimed to determine whether expiratory abdominal muscle thickness assessed by ultrasonography (US) was associated with 28-day mortality in ICU patients.
Basic procedures |
US expiratory abdominal muscle thickness was measured within the first 12 h after ICU admission. The primary endpoint was 28-day mortality.
Main findings |
In 310 analyzed patients, a thinner total abdominal expiratory muscle thickness at admission was associated with 28-day mortality (median value with interquartile range: 10.8 [10; 14.6] versus 16.5 [13.4; 20.7] mm). Total abdominal expiratory muscle thickness had an area under the curve of 0.78 [0.71;0.86] to discriminate 28-day mortality.
Conclusions |
US expiratory abdominal muscle thickness was associated with 28-day mortality, supporting its use in predicting ICU patient outcome.
Le texte complet de cet article est disponible en PDF.Keywords : Point-of-care ultrasound, Expiratory muscle thickness, Intensive care unit, Frailty
Plan
Vol 42 - N° 5
Article 101252- octobre 2023 Retour au numéro
Article précédent
- Anxiety and depression symptoms in relatives of moderate-to-severe traumatic brain injury survivors — A multicentre cohort
- Raphaël Cinotti, Alice Chopin, Jean Denis Moyer, Olivier Huet, Sigismond Lasocki, Benjamin Cohen, Claire Dahyot-Fizelier, Kevin Chalard, Philippe Seguin, Florian Pierre Martin, Céline Lerebourg, Marie Guitteny, Amandine Chenet, Brigitte Perrouin-Verbe, Karim Asehnoune, Fanny Feuillet, Véronique Sébille, Antoine Roquilly, for the Atlanréa Group and the Société Française d’Anesthésie-Réanimation–SFAR Research Network
- A prospective phase IIA multicenter double-blinded randomized placebo-controlled clinical trial evaluating the efficacy and safety of inhaled Tobramycin in patients with ventilator-associated pneumonia (iToVAP)
- Stefan Angermair, Maria Deja, Anja Thronicke, Claudia Grehn, Nilufar Akbari, Alexander Uhrig, Golschan Asgarpur, Claudia Spies, Sascha Treskatsch, Carsten Schwarz
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?